Novaliq’s Supervisory Board is responsible for the Management Team as well as supervising the company. The Supervisory Board is currently composed of the following members:
Dr. Friedrich von Bohlen
Dr. Friedrich von Bohlen and Halbach is Managing Director and co-founder of the dievini Hopp BioTech holding GmbH & Co KG. dievini manages the Biotech investments of the SAP co-founder Dietmar Hopp and his family. Friedrich von Bohlen studied Biochemistry at the University of Zurich and graduated in Neuroscience at the ETH Zurich. Afterwards he worked in different positions at Fresenius AG, at FAG Kugelfischer KGaA and at WASAG Chemie AG.
In 1997 he founded the LION bioscience AG (now Sygnis Pharma AG), where he was the CEO for seven years. Since then he has been a member of the board of Sygnis AG, the successor of LION. Today is also the chairman of the board of Apogenix GmbH, CureVac GmbH and Molecular Health GmbH. He is also a member of the board of Cosmo Pharmaceuticals SpA, Cytonet GmbH, immatics biotechnologies GmbH, Novaliq GmbH, Wilex AG and the Wyss Translational Centers Zurich.
Dr. Gerald D. Cagle
Dr. Cagle began his career as an academic, serving as a faculty member of The Ohio State University in Columbus. Thereafter, and for more than three decades, he worked as a member of Alcon’s research and development team. In 1996, Dr. Cagle was named Senior Vice President of Alcon R&D and Chief Scientific Officer, a position he held until mid-2008. As head of Alcon R&D, he led the global activities of some 1,300 scientists stationed around the world. The productivity of the R&D organization, and the new products introduced during his tenure, have been recognized as a primary contributor to Alcon’s significant growth. Following his departure from Alcon, he worked on the management of Alzheimer’s disease. He serves on the Board of Aerie Pharmaceuticals, Clearside Biomedical, AB2, and GrayBug. Dr. Cagle received his BS degree from Wayland College in Plainview, Texas, and earned both his MS and PhD degrees from the University of North Texas in Denton, Texas.
Mr. Geuder is CEO and managing director of the Geuder Group and Geuder AG in Heidelberg, Germany.
The Geuder AG has been one of the most innovative eye surgical product manufacturers for the past 65 years. Ophthalmic surgeons in over 90 countries rely on more than 3,000 Geuder products when performing surgical operations.
Mr Geuder is also managing director of the Fluoron® GmbH in Ulm, Germany an affiliate of the Geuder AG. Fluoron GmbH develops and manufactures ultrapure innovative biomaterials for retinal and cataract surgery. Fluoron GmbH plays a leading role in this field worldwide.
Dr. Mathias Hothum
Dr. Mathias Hothum, owner of HMM-Consulting, received his diploma in Economics from the University of Mannheim. He went on to complete his doctorate at the University of Magdeburg.
For the past 20 years, Dr. Hothum has gained experience as a health economist in the sectors of healthcare, health service and life sciences. He specializes in pricing, reimbursement and in the evaluation of medium-sized companies and publicly owned/market-listed companies.
Dr. Hothum is managing director of dievini Hopp BioTech holding GmbH & Co. KG – Advisors in Health Sciences. His focus is on controlling and strategy planning for portfolio companies.
Dr. Thomas Kaercher
Thomas Kaercher is an independent ophthalmologist in Heidelberg, Germany.
Dr. Kaercher graduated with a medical degree from Heidelberg University and undertook further training at the University of London, UK, before specialising in ophthalmology at Heidelberg University`s ophthalmic hospital. He worked as a senior physician at the ophthalmic hospital of Ludwigshafen, Germany.
Dr. Kaercher`s research interests include dry eye, Meibomian gland diseases, ocular surface diseases, contact lenses and ectodermal dysplasia syndromes. He is a member of the German Ophthalmologic Society, and the Association of German Ophthalmologists. He also works as one of the four members of the German Dry Eye Group. He is active in the scientific board of the German-speaking patient support group for ectodermal dysplasia and is a member of the judging panel for the German Sicca Award.
Berthold Wipfler is a co-founder of Wipfler & Partner in Walldorf, a tax advisory and business consulting firm specialising in corporate transactions and structuring. Leading international firms such as SAP, as well as SAP founders Dietmar Hopp and Hasso Plattner are amongst his long-term clients. Before starting his own consulting business as a certified tax consultant Mr. Wipfler held executive positions in the fiscal administration of the Land of Baden-Württemberg from 1969 to 1985. In his last position, Mr. Wipfler was responsible for the Department of Audit, Investigation of Suspected Tax Offences, Criminal Matters and Fines at the Regional Tax Office in Karlsruhe. During his academic career Mr. Wipfler was a lecturer at the School of Finance in Karlsruhe and Technical University for Finance in Ludwigsburg as well as at the Bundesfinanzakademie Siegburg (1969 – 1985). Mr. Wipfler holds a Master of Fiscal Affairs from the Technical University for Finance.He is also the executive managing director of the Hasso-Plattner-Stiftung für Softwaresystemtechnik, Potsdam; a member of the board of trustees of Hochschule Karlsruhe for Technology and Economics; and a member of a wide variety of supervisory boards.